Kirsten R. PalmerTu’uhevaha J. Kaitu’u‐LinoPing CannonLaura TuoheyManarangi S. De SilvaManuel Varas‐GodoyStephanie Maia AcuñaJosé GalazStephen TongSebastián E. Illanes2026-03-222026-03-22201610.1080/14767058.2016.1182975https://doi.org/10.1080/14767058.2016.1182975https://andeanlibrary.org/handle/123456789/47625Citaciones: 15Plasma sFLT-1 e15a is significantly increased in early-onset preeclampsia and term fetal growth restriction. Further assessment of the benefit for sFLT-1 e15a testing in prediction or diagnosis of these disease states is warranted.enPreeclampsiaProspective cohort studyFetusMedicineCohortBiomarkerFetal growthIntrauterine growth restrictionPregnancyObstetricsMaternal plasma concentrations of the placental specific sFLT-1 variant, sFLT-1 e15a, in fetal growth restriction and preeclampsiaarticle